Chimeric antigen receptor (CAR) T cells are engineered constructs composed of synthetic receptors that direct T cells to surface antigens for subsequent elimination. Many CAR constructs are also manufactured with elements that augment T-cell persistence and activity. To date, CAR T cells have demonstrated tremendous success in eradicating hematological malignancies (e.g., CD19 CARs in leukemias). This success is not yet extrapolated to solid tumors, and the reasons for this are being actively investigated. Here in this mini-review, we discuss some of the key hurdles encountered by CAR T cells in the solid tumor microenvironment.

中文翻译：

---

嵌合抗原受体T细胞疗法用于实体瘤。

嵌合抗原受体（CAR）T细胞是由合成受体组成的工程构建体，这些受体将T细胞引导至表面抗原以进行后续消除。许多CAR构造也使用增加T细胞持久性和活性的元素来制造。迄今为止，CAR T细胞在根除血液恶性肿瘤（例如白血病中的CD19 CAR）方面已显示出巨大的成功。这种成功尚未推断到实体瘤，并且正在积极研究其原因。在此微型审查中，我们讨论了实体瘤微环境中CAR T细胞遇到的一些关键障碍。